Large-Addressable Market Hepion targets early liver cancer detection with liquid biopsy assays, addressing a rapidly growing market in oncology diagnostics and a high-need segment (high-risk cirrhotic patients), offering a broad potential customer base among research institutions, hospitals, and diagnostic partners.

Strategic IP Edge Two global rights to first-in-class tests (mSEPT9 methylation and ctRNA platform) provide defensible technology and clear differentiators in sensitivity and stage discrimination, enabling value propositions for premium partnerships and license deals.

Theranostics Synergy Hepion’s aim to integrate diagnostics and therapeutics in a closed-loop theranostics model creates collaboration opportunities with pharma/biotech companies seeking companion diagnostics or co-development with oncology therapies.

Partnership Focused Recent licenses and collaborations with Cirna Diagnostics and New Day Diagnostics, plus prior strategic moves, indicate a business development approach centered on expanding asset capabilities and market reach through licensing and partnerships.

Financial Leverage With substantial funding (~$145M) despite current <$1M revenue, Hepion looks positioned to fund clinical expansion and partner deals, presenting opportunities for investment, milestone-based collaborations, and co-development arrangements.